e-Drug3D 580 |
cas 59122-46-2 |
CLASS METABOLISM |
ROUTE (list) ORAL |
PK parameters Solubility SOLUBLE IN WATER |
Target TARGET PROSTAGLANDIN RECEPTOR |
DrugCentral Prostaglandin E2 receptor EP3 subtype UNIPROT P43115 PTGER3 |
Download SDF file | methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate Formula: Calculated chemical properties: MW 382.52 NB_atoms 27 XLogP 3.95 PSA 83.23 NB_HD 2 NB_HA 5 fsp3 0.82 Lipinski(0=no;1=yes) 1 |
FDA NDA 019268 (pdf not found) INN (MISOPROSTOL) CYTOTEC (PFIZER) APPROVAL= AP YEAR= 1988 NDA 020607 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) ARTHROTEC (PFIZER) APPROVAL= AP YEAR= 1997 NDA 076095 (pdf not found) INN (MISOPROSTOL) MISOPROSTOL (ANI PHARMS) APPROVAL= AP YEAR= 2002 NDA 091667 (pdf not found) INN (MISOPROSTOL) MISOPROSTOL (NOVEL LABS INC) APPROVAL= AP YEAR= 2012 DISCONTINUED NDA 201089 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (ACTAVIS LABS FL INC) APPROVAL= AP YEAR= 2012 NDA 200158 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (SANDOZ) APPROVAL= AP YEAR= 2013 NDA 200540 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (EXELA HOLDINGS) APPROVAL= AP YEAR= 2014 DISCONTINUED NDA 203995 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (AMNEAL PHARMS) APPROVAL= AP YEAR= 2016 NDA 210201 (pdf not found) INN (MISOPROSTOL) MISOPROSTOL (ACQ PHARMA) APPROVAL= AP YEAR= 2019 NDA 205143 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (YUNG SHIN PHARM) APPROVAL= AP YEAR= 2020 NDA 204355 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (MICRO LABS) APPROVAL= AP YEAR= 2021 NDA 216872 (pdf not found) INN (MISOPROSTOL) MISOPROSTOL (MICRO LABS) APPROVAL= AP YEAR= 2022 NDA 206771 (pdf not found) INN (DICLOFENAC SODIUM ; MISOPROSTOL) DICLOFENAC SODIUM AND MISOPROSTOL (ZYDUS PHARMS) APPROVAL= AP YEAR= 2023 DISCONTINUED |
Other links: |